Xiaoyang Liu

Adjuvant lenvatinib plus transarterial chemoembolization is associated with better outcomes than gemcitabine plus cisplatin in combined hepatocellular cholangiocarcinoma

To evaluate and compare the efficacy and safety of lenvatinib combined with transarterial chemoembolization (TACE) and gemcitabine plus cisplatin (GP) as adjuvant treatments for combined hepatocellular-cholangiocarcinoma (cHCC-CCA), and to explore the differential therapeutic ben...